LGG-56. TREATMENT WITH VEMURAFENIB IN PEDIATRIC PATIENTS WITH LOW-GRADE GLIOMAS WITH BRAF V600E MUTATION. REPORT OF 4 CASES

摘要

BACKGROUNDBRAF mutations, resulting in aberrant activation of the MAPK pathways are critical in low grade gliomas (LGG) pathogenesis. BRAF V600E mutation (BRAF V600E +) is present in 10 - 20% of this tumors, mostly in Pleomorphic Xanthotrocytoma (PXA) and gangliogliomas. Vemurafenib has shown efficacy on patients with LGG by inhibition of BRAF serine-threonine kinase.